Opioid REceptors on Lymphocytes and Brain

淋巴细胞和大脑上的阿片受体

基本信息

  • 批准号:
    6848731
  • 负责人:
  • 金额:
    $ 11.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-02-01 至 2008-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This K05 Senior Scientist Award is to support Dr. Jean M. Bidlack's research activities. The specific aim of this award is to provide Dr. Bidlack with some release time from grant writing, teaching and administrative responsibilities to cover her salary. This award will allow her to devote the majority of her time to research and the training of graduate students and postdoctoral fellows. Training activities will be supported by a NIDA Training Grant (T32 DA07232). Dr. Bidlack will expand her research background and expertise in studying the expression and regulation of opioid receptors on immune cells. Also, she will investigate whether a chemokine receptor expressed on human herpes virus -6 and -7 binds opioids, and if opioids alter chemokine activation of the receptor. This chemokine receptor, U51, shares considerable amino acid sequence homology and similarity with the kappa opioid receptor. In addition, ongoing studies directed at medications development for the treatment of heroin and cocaine abuse will continue. The working hypothesis for which we have produced experimental support is that compounds, which release dopamine from the nucleus accumbens, promote drug-seeking behavior and those, which prevent release of this transmitter, prevent drug-seeking behavior. It is known that kappa agonists and mu antagonists inhibit dopamine release in the nucleus accumbens. Studies are further defining properties of select compounds that make some ? agonists with varying activity at mu receptors better at reducing cocaine self-administration in nonhuman primates than other compounds. In collaboration with chemists and behaviorists, we are evaluated new opioids as potential pharmacotherapeutics for treating drug abuse. The goals of these three independent projects will be accomplished within the framework of two R01 grants, a R21 grant, and three subcontracts from NIDA. Collectively, these projects will provide new information on the localization and function of the multiple opioid receptors on immune cells and on the human herpes viruses -6 and -7. Also, they will advance efforts in developing drugs to treat cocaine and heroin abuse. The present proposal is being requested in order to provide the candidate with stability of support, which is necessary for her continued commitment to research in the field of drug abuse and to ensure her sustained high level of productivity as both a senior scientist, and as a mentor for trainees, who will be the next generation of drug abuse researchers.
描述(由申请人提供): K 05高级科学家奖旨在支持Jean M. Bidlack的研究活动。该奖项的具体目的是为比德莱克博士提供一些从赠款写作,教学和行政责任中解脱出来的时间,以支付她的工资。该奖项将使她能够将大部分时间用于研究和研究生和博士后研究员的培训。培训活动将得到NIDA培训补助金(T32 DA 07232)的支持。Bidlack博士将扩大她在研究免疫细胞上阿片受体的表达和调节方面的研究背景和专业知识。此外,她还将研究人类疱疹病毒-6和-7上表达的趋化因子受体是否与阿片类药物结合,以及阿片类药物是否会改变趋化因子对受体的激活。这种趋化因子受体U 51与κ阿片受体具有相当大的氨基酸序列同源性和相似性。此外,将继续进行针对开发治疗海洛因和可卡因滥用的药物的研究。我们已经得到实验支持的工作假设是,从脑桥核释放多巴胺的化合物会促进觅药行为,而那些阻止这种递质释放的化合物会阻止觅药行为。已知κ激动剂和μ拮抗剂抑制丘脑核中的多巴胺释放。研究正在进一步确定选择的化合物的性质,使一些?对μ受体具有不同活性的激动剂在减少非人灵长类动物中可卡因自我给药方面比其它化合物更好。与化学家和行为学家合作,我们评估了新的阿片类药物作为治疗药物滥用的潜在药物治疗剂。这三个独立项目的目标将在两个R 01赠款,一个R21赠款和NIDA的三个分包合同的框架内完成。总的来说,这些项目将提供关于免疫细胞和人类疱疹病毒-6和-7上多种阿片受体的定位和功能的新信息。此外,他们还将推动开发治疗可卡因和海洛因滥用的药物的努力。请求提出本建议是为了向候选人提供稳定的支助,这是她继续致力于药物滥用领域的研究所必需的,并确保她作为一名资深科学家和作为将成为下一代药物滥用研究人员的受训人员的导师保持高水平的生产力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEAN M BIDLACK其他文献

JEAN M BIDLACK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEAN M BIDLACK', 18)}}的其他基金

G alpha Z subunit as a potential therapeutic target to modulate mu opioid receptor pharmacology
G α Z 亚基作为调节 mu 阿片受体药理学的潜在治疗靶点
  • 批准号:
    10580415
  • 财政年份:
    2022
  • 资助金额:
    $ 11.93万
  • 项目类别:
38th Annual International Narcotics Research Conference
第 38 届国际麻醉品研究年度会议
  • 批准号:
    7334676
  • 财政年份:
    2007
  • 资助金额:
    $ 11.93万
  • 项目类别:
37th Annual International Narcotics Research Conference
第 37 届国际麻醉品研究年度会议
  • 批准号:
    7167690
  • 财政年份:
    2006
  • 资助金额:
    $ 11.93万
  • 项目类别:
36th Annual International Narcotics Research Conference
第 36 届国际麻醉品研究年度会议
  • 批准号:
    7005344
  • 财政年份:
    2005
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid Binding to U51: A Human herpes Virus Protein
阿片类药物与 U51 结合:人类疱疹病毒蛋白
  • 批准号:
    6447741
  • 财政年份:
    2001
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid Binding to U51: A Human herpes Virus Protein
阿片类药物与 U51 结合:人类疱疹病毒蛋白
  • 批准号:
    6523577
  • 财政年份:
    2001
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid REceptors on Lymphocytes and Brain
淋巴细胞和大脑上的阿片受体
  • 批准号:
    6573588
  • 财政年份:
    1998
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid REceptors on Lymphocytes and Brain
淋巴细胞和大脑上的阿片受体
  • 批准号:
    6702541
  • 财政年份:
    1998
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid REceptors on Lymphocytes and Brain
淋巴细胞和大脑上的阿片受体
  • 批准号:
    7173433
  • 财政年份:
    1998
  • 资助金额:
    $ 11.93万
  • 项目类别:
Opioid REceptors on Lymphocytes and Brain
淋巴细胞和大脑上的阿片受体
  • 批准号:
    7017098
  • 财政年份:
    1998
  • 资助金额:
    $ 11.93万
  • 项目类别:

相似海外基金

Investigating ubiquitination-regulated cell cycle events underpinning malaria transmission
研究泛素化调节的细胞周期事件支撑疟疾传播
  • 批准号:
    MR/Y013174/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.93万
  • 项目类别:
    Research Grant
Investigating cell cycle vulnerabilities in TP53 mutant cancers
研究 TP53 突变癌症的细胞周期脆弱性
  • 批准号:
    MR/Y01264X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.93万
  • 项目类别:
    Research Grant
Conference: FASEB Yeast Chromosome and Cell Cycle Conference 2024
会议:2024 年 FASEB 酵母染色体和细胞周期会议
  • 批准号:
    2403471
  • 财政年份:
    2024
  • 资助金额:
    $ 11.93万
  • 项目类别:
    Standard Grant
MRC TS Award: Regulation of neutrophil functions by cell cycle proteins
MRC TS 奖:细胞周期蛋白调节中性粒细胞功能
  • 批准号:
    MR/X023087/1
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
    Fellowship
Cell cycle timing and molecular mechanisms of structural variant formation following incomplete replication
不完全复制后结构变异形成的细胞周期时间和分子机制
  • 批准号:
    10656861
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
Developmental regulation of the cell cycle machinery
细胞周期机制的发育调控
  • 批准号:
    10714634
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
Cell cycle control of cell polarity and fate in epidermal morphogenesis
表皮形态发生中细胞极性和命运的细胞周期控制
  • 批准号:
    10608036
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
Cell cycle-dependent dynein adaptor switching
细胞周期依赖性动力蛋白适配器转换
  • 批准号:
    23KF0285
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Cell cycle control of adipogenesis
脂肪生成的细胞周期控制
  • 批准号:
    10668721
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
Regulation of Cell Cycle progression by the nuclear envelope
核膜对细胞周期进程的调节
  • 批准号:
    10659597
  • 财政年份:
    2023
  • 资助金额:
    $ 11.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了